View Future GrowthKaneka 과거 순이익 실적과거 기준 점검 4/6Kaneka은 연평균 2.2%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 4.4% 감소했습니다. 매출은 연평균 5.4%의 비율로 증가했습니다. Kaneka의 자기자본이익률은 6.2%이고 순이익률은 3.8%입니다.핵심 정보2.16%순이익 성장률3.30%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률5.43%자기자본이익률6.25%순이익률3.82%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026공시 • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026공시 • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025공시 • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025공시 • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025모든 업데이트 보기Recent updatesReported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.공시 • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026공시 • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026공시 • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.공시 • Nov 10Kaneka Expands Global Reach with i-ED COIL Launch in EuropeKaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.공시 • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025공시 • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025공시 • May 16Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.공시 • May 14Kaneka Corporation, Annual General Meeting, Jun 27, 2025Kaneka Corporation, Annual General Meeting, Jun 27, 2025.공시 • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025공시 • Jan 09Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd.Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.공시 • Dec 21Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: JP¥49.73 (vs JP¥71.73 in 2Q 2024)Second quarter 2025 results: EPS: JP¥49.73 (down from JP¥71.73 in 2Q 2024). Revenue: JP¥197.6b (up 5.4% from 2Q 2024). Net income: JP¥3.13b (down 33% from 2Q 2024). Profit margin: 1.6% (down from 2.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years.Upcoming Dividend • Sep 20Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 05 December 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.0%).공시 • Sep 18Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €20.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €16.18 per share.공시 • Jun 18Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024Reported Earnings • May 19Full year 2024 earnings released: EPS: JP¥358 (vs JP¥350 in FY 2023)Full year 2024 results: EPS: JP¥358 (up from JP¥350 in FY 2023). Revenue: JP¥762.3b (flat on FY 2023). Net income: JP¥23.2b (flat on FY 2023). Profit margin: 3.0% (in line with FY 2023). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year.공시 • May 16Kaneka Corporation, Annual General Meeting, Jun 27, 2024Kaneka Corporation, Annual General Meeting, Jun 27, 2024.Upcoming Dividend • Mar 21Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (4.8%).공시 • Mar 13Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥69.95 (vs JP¥34.88 in 3Q 2023)Third quarter 2024 results: EPS: JP¥69.95 (up from JP¥34.88 in 3Q 2023). Revenue: JP¥194.6b (up 4.3% from 3Q 2023). Net income: JP¥4.54b (up 96% from 3Q 2023). Profit margin: 2.3% (up from 1.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.Buying Opportunity • Jan 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €27.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 7.0%. Revenue is forecast to grow by 8.9% in 2 years. Earnings is forecast to grow by 92% in the next 2 years.공시 • Nov 30Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: JP¥71.73 (vs JP¥91.80 in 2Q 2023)Second quarter 2024 results: EPS: JP¥71.73 (down from JP¥91.80 in 2Q 2023). Revenue: JP¥187.4b (flat on 2Q 2023). Net income: JP¥4.66b (down 23% from 2Q 2023). Profit margin: 2.5% (down from 3.2% in 2Q 2023). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 21Upcoming dividend of JP¥55.00 per share at 2.7% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 43% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (5.9%).공시 • Sep 13Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023New Risk • Aug 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.2% Last year net profit margin: 4.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.2% net profit margin).Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: JP¥65.35 (vs JP¥161 in 1Q 2023)First quarter 2024 results: EPS: JP¥65.35 (down from JP¥161 in 1Q 2023). Revenue: JP¥182.7b (down 5.2% from 1Q 2023). Net income: JP¥4.24b (down 60% from 1Q 2023). Profit margin: 2.3% (down from 5.5% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.공시 • Jun 15Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023Reported Earnings • May 18Full year 2023 earnings released: EPS: JP¥350 (vs JP¥406 in FY 2022)Full year 2023 results: EPS: JP¥350 (down from JP¥406 in FY 2022). Revenue: JP¥755.8b (up 9.3% from FY 2022). Net income: JP¥23.0b (down 13% from FY 2022). Profit margin: 3.0% (down from 3.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • May 17Kaneka Corporation, Annual General Meeting, Jun 29, 2023Kaneka Corporation, Annual General Meeting, Jun 29, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥55.00 per share at 3.3% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 13 June 2023. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.7%).Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: JP¥34.87 (vs JP¥111 in 3Q 2022)Third quarter 2023 results: EPS: JP¥34.87 (down from JP¥111 in 3Q 2022). Revenue: JP¥186.5b (up 4.5% from 3Q 2022). Net income: JP¥2.32b (down 68% from 3Q 2022). Profit margin: 1.2% (down from 4.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Dec 17Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Yuko Sasakawa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: JP¥91.80 (vs JP¥107 in 2Q 2022)Second quarter 2023 results: EPS: JP¥91.80 (down from JP¥107 in 2Q 2022). Revenue: JP¥187.9b (up 13% from 2Q 2022). Net income: JP¥6.05b (down 14% from 2Q 2022). Profit margin: 3.2% (down from 4.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (6.1%).공시 • Sep 10+ 1 more updateKaneka Corporation (TSE:4118) announces an Equity Buyback for 2,300,000 shares, representing 3.42% for ¥10,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 2,300,000 shares, representing 3.42% of the outstanding shares for ¥10,000 million. The purpose of the program is to improve shareholder value and to implement a flexible capital policy in response to changes in the business environment. The program will run until March 24, 2022. As of August 31, 2022, the company had 67,195,241 shares outstanding and 804,759 shares in treasury.Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥161 (vs JP¥119 in 1Q 2022)First quarter 2023 results: EPS: JP¥161 (up from JP¥119 in 1Q 2022). Revenue: JP¥192.7b (up 17% from 1Q 2022). Net income: JP¥10.5b (up 36% from 1Q 2022). Profit margin: 5.5% (up from 4.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.2%, compared to a 2.9% growth forecast for the industry in Germany.공시 • Jun 11Kaneka Corporation to Report Q1, 2023 Results on Aug 10, 2022Kaneka Corporation announced that they will report Q1, 2023 results on Aug 10, 2022Reported Earnings • May 15Full year 2022 earnings released: EPS: JP¥406 (vs JP¥243 in FY 2021)Full year 2022 results: EPS: JP¥406 (up from JP¥243 in FY 2021). Revenue: JP¥691.5b (up 20% from FY 2021). Net income: JP¥26.5b (up 67% from FY 2021). Profit margin: 3.8% (up from 2.7% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.3%, compared to a 6.4% growth forecast for the industry in Germany.공시 • May 14Kaneka Corporation, Annual General Meeting, Jun 29, 2022Kaneka Corporation, Annual General Meeting, Jun 29, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Managing Executive Officer & Director Katsunobu Doro was the last director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buying Opportunity • Apr 21Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €31.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 9.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings is also forecast to grow by 6.8% per annum over the same time period.공시 • Apr 13Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) VariantsKaneka Corporation released KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta) ver.2”, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19. This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test. This is expected to help reduce the burden placed by testing and to assist with selecting the best suitable drugs and treatment approaches for each variant in clinical settings. Kaneka has already released the KANEKA Direct RT-PCR Kit SARS-CoV-2, an in-vitro diagnostic reagent that uses Kaneka's original sample processing technology to produce test results in less than an hour, KANEKA RT-PCR Kit “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which can detect four variants simultaneously, and KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta)” which can detect the Delta and Omicron variants of COVID-19. These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers. These products make it possible to quickly test large numbers of samples.Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (4.7%).Reported Earnings • Feb 09Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥111 (up from JP¥110 in 3Q 2021). Revenue: JP¥178.4b (up 15% from 3Q 2021). Net income: JP¥7.26b (up 1.0% from 3Q 2021). Profit margin: 4.1% (down from 4.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.9%. Over the next year, revenue is forecast to stay flat compared to a 6.0% growth forecast for the industry in Germany.Reported Earnings • Nov 10Second quarter 2022 earnings released: EPS JP¥107 (vs JP¥31.26 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥166.2b (up 19% from 2Q 2021). Net income: JP¥7.01b (up 244% from 2Q 2021). Profit margin: 4.2% (up from 1.5% in 2Q 2021). The increase in margin was driven by higher revenue.Upcoming Dividend • Sep 22Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 07 December 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.7%).Reported Earnings • Aug 14First quarter 2022 earnings released: EPS JP¥119 (vs JP¥6.70 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥164.1b (up 30% from 1Q 2021). Net income: JP¥7.76b (up JP¥7.32b from 1Q 2021). Profit margin: 4.7% (up from 0.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • May 16Full year 2021 earnings released: EPS JP¥243 (vs JP¥215 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥577.4b (down 4.0% from FY 2020). Net income: JP¥15.8b (up 13% from FY 2020). Profit margin: 2.7% (up from 2.3% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Mar 24Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.6%).Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥39.40, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Chemicals industry in Germany. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €24.18 per share.공시 • Mar 11Kaneka Corporation to Report Fiscal Year 2021 Results on May 13, 2021Kaneka Corporation announced that they will report fiscal year 2021 results on May 13, 2021Is New 90 Day High Low • Feb 16New 90-day high: €32.60The company is up 29% from its price of €25.20 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.16 per share.Reported Earnings • Feb 11Third quarter 2021 earnings released: EPS JP¥110 (vs JP¥48.85 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥154.8b (up 1.4% from 3Q 2020). Net income: JP¥7.18b (up 125% from 3Q 2020). Profit margin: 4.6% (up from 2.1% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Feb 11Revenue beats expectationsRevenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.3%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.Is New 90 Day High Low • Jan 26New 90-day high: €30.00The company is up 26% from its price of €23.80 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.58 per share.Is New 90 Day High Low • Jan 08New 90-day high: €29.20The company is up 16% from its price of €25.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.44 per share.공시 • Dec 17Kaneka Corporation to Report Q3, 2021 Results on Feb 09, 2021Kaneka Corporation announced that they will report Q3, 2021 results on Feb 09, 2021Is New 90 Day High Low • Dec 17New 90-day high: €28.40The company is up 19% from its price of €23.80 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.62 per share.Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 1.1%, compared to a 3.6% growth forecast for the Chemicals industry in Germany.Is New 90 Day High Low • Nov 12New 90-day high: €25.80The company is up 22% from its price of €21.20 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.41 per share.Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS JP¥31.26The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥140.1b (down 7.3% from 2Q 2020). Net income: JP¥2.04b (down 20% from 2Q 2020). Profit margin: 1.5% (down from 1.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 12New 90-day high: €25.60The company is up 21% from its price of €21.20 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.76 per share.Is New 90 Day High Low • Sep 18New 90-day high: €24.80The company is up 8.0% from its price of €23.00 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.11 per share.공시 • Sep 13Kaneka Corporation to Report Q2, 2021 Results on Nov 10, 2020Kaneka Corporation announced that they will report Q2, 2021 results on Nov 10, 2020공시 • Jun 28Kaneka Corporation to Report Q1, 2021 Results on Aug 12, 2020Kaneka Corporation announced that they will report Q1, 2021 results on Aug 12, 2020매출 및 비용 세부 내역Kaneka가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:KKA 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Mar 26811,63830,977192,655031 Dec 25802,43026,013189,988030 Sep 25808,66526,196140,41339,34230 Jun 25807,50022,537186,487031 Mar 25807,20025,309137,84639,34231 Dec 24800,62227,518139,56535,39730 Sep 24788,14924,485135,88635,39730 Jun 24777,94426,012132,77535,39731 Mar 24762,30223,220128,39835,39731 Dec 23753,40617,556127,31932,66930 Sep 23745,33515,337124,86332,66930 Jun 23745,82216,731123,76632,66931 Mar 23755,82123,008123,86032,66931 Dec 22749,95723,356126,37430,89430 Sep 22741,86528,289124,81330,89430 Jun 22720,16329,248120,47530,89431 Mar 22691,53026,487115,97430,89431 Dec 21664,65828,193115,79427,82030 Sep 21640,97928,121112,27527,82030 Jun 21614,88823,151108,99727,82031 Mar 21577,42615,831105,54227,82031 Dec 20570,53114,430103,71329,38930 Sep 20568,37310,433103,85729,38930 Jun 20579,33610,949105,99329,38931 Mar 20601,51414,003107,86129,38931 Dec 19605,89516,789107,63928,96330 Sep 19614,84517,598107,08828,96330 Jun 19617,59419,444105,79228,96331 Mar 19621,04322,238104,41428,96331 Dec 18617,82620,517103,16628,03930 Sep 18609,93722,642101,40828,03930 Jun 18604,11123,09599,89828,03931 Mar 18596,14221,57199,01128,03931 Dec 17586,07123,26798,69028,51330 Sep 17570,29820,95697,35628,51330 Jun 17556,46620,64595,88028,51331 Mar 17548,22220,48496,31428,51331 Dec 16546,10517,53698,56526,76730 Sep 16545,56620,21996,38726,76730 Jun 16551,91120,43594,89626,76731 Mar 16555,22720,98591,96726,76731 Dec 15555,38824,38992,80423,31930 Sep 15558,66422,50491,56923,31930 Jun 15555,62220,20389,14423,319양질의 수익: KKA는 ¥13.4B 규모의 큰 일회성 이익이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: KKA의 현재 순 이익률 (3.8%)은 지난해 (3.1%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: KKA의 수익은 지난 5년 동안 연평균 2.2% 증가했습니다.성장 가속화: 지난 1년간 KKA 의 수익 증가율(22.4%)은 연간 평균(2.2%)을 초과합니다.수익 대 산업: KKA의 지난 1년 수익 증가율(22.4%)은 Chemicals 업계의 -13.5%를 상회했습니다.자기자본이익률높은 ROE: KKA의 자본 수익률(6.2%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 01:21종가2026/05/22 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kaneka Corporation는 16명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kyoji ChibaBofA Global ResearchTakao KanaiCitigroup IncKeita IkedaDaiwa Securities Co. Ltd.13명의 분석가 더 보기
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026
공시 • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026
공시 • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
공시 • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
공시 • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.
공시 • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026
공시 • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026
공시 • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.
공시 • Nov 10Kaneka Expands Global Reach with i-ED COIL Launch in EuropeKaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.
공시 • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
공시 • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
공시 • May 16Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.
공시 • May 14Kaneka Corporation, Annual General Meeting, Jun 27, 2025Kaneka Corporation, Annual General Meeting, Jun 27, 2025.
공시 • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025
공시 • Jan 09Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd.Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.
공시 • Dec 21Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025
Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: JP¥49.73 (vs JP¥71.73 in 2Q 2024)Second quarter 2025 results: EPS: JP¥49.73 (down from JP¥71.73 in 2Q 2024). Revenue: JP¥197.6b (up 5.4% from 2Q 2024). Net income: JP¥3.13b (down 33% from 2Q 2024). Profit margin: 1.6% (down from 2.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 05 December 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.0%).
공시 • Sep 18Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €20.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €16.18 per share.
공시 • Jun 18Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
Reported Earnings • May 19Full year 2024 earnings released: EPS: JP¥358 (vs JP¥350 in FY 2023)Full year 2024 results: EPS: JP¥358 (up from JP¥350 in FY 2023). Revenue: JP¥762.3b (flat on FY 2023). Net income: JP¥23.2b (flat on FY 2023). Profit margin: 3.0% (in line with FY 2023). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year.
공시 • May 16Kaneka Corporation, Annual General Meeting, Jun 27, 2024Kaneka Corporation, Annual General Meeting, Jun 27, 2024.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (4.8%).
공시 • Mar 13Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥69.95 (vs JP¥34.88 in 3Q 2023)Third quarter 2024 results: EPS: JP¥69.95 (up from JP¥34.88 in 3Q 2023). Revenue: JP¥194.6b (up 4.3% from 3Q 2023). Net income: JP¥4.54b (up 96% from 3Q 2023). Profit margin: 2.3% (up from 1.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
Buying Opportunity • Jan 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €27.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 7.0%. Revenue is forecast to grow by 8.9% in 2 years. Earnings is forecast to grow by 92% in the next 2 years.
공시 • Nov 30Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: JP¥71.73 (vs JP¥91.80 in 2Q 2023)Second quarter 2024 results: EPS: JP¥71.73 (down from JP¥91.80 in 2Q 2023). Revenue: JP¥187.4b (flat on 2Q 2023). Net income: JP¥4.66b (down 23% from 2Q 2023). Profit margin: 2.5% (down from 3.2% in 2Q 2023). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥55.00 per share at 2.7% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 43% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (5.9%).
공시 • Sep 13Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023
New Risk • Aug 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.2% Last year net profit margin: 4.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.2% net profit margin).
Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: JP¥65.35 (vs JP¥161 in 1Q 2023)First quarter 2024 results: EPS: JP¥65.35 (down from JP¥161 in 1Q 2023). Revenue: JP¥182.7b (down 5.2% from 1Q 2023). Net income: JP¥4.24b (down 60% from 1Q 2023). Profit margin: 2.3% (down from 5.5% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
공시 • Jun 15Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023
Reported Earnings • May 18Full year 2023 earnings released: EPS: JP¥350 (vs JP¥406 in FY 2022)Full year 2023 results: EPS: JP¥350 (down from JP¥406 in FY 2022). Revenue: JP¥755.8b (up 9.3% from FY 2022). Net income: JP¥23.0b (down 13% from FY 2022). Profit margin: 3.0% (down from 3.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • May 17Kaneka Corporation, Annual General Meeting, Jun 29, 2023Kaneka Corporation, Annual General Meeting, Jun 29, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥55.00 per share at 3.3% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 13 June 2023. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.7%).
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: JP¥34.87 (vs JP¥111 in 3Q 2022)Third quarter 2023 results: EPS: JP¥34.87 (down from JP¥111 in 3Q 2022). Revenue: JP¥186.5b (up 4.5% from 3Q 2022). Net income: JP¥2.32b (down 68% from 3Q 2022). Profit margin: 1.2% (down from 4.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Dec 17Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Yuko Sasakawa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: JP¥91.80 (vs JP¥107 in 2Q 2022)Second quarter 2023 results: EPS: JP¥91.80 (down from JP¥107 in 2Q 2022). Revenue: JP¥187.9b (up 13% from 2Q 2022). Net income: JP¥6.05b (down 14% from 2Q 2022). Profit margin: 3.2% (down from 4.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (6.1%).
공시 • Sep 10+ 1 more updateKaneka Corporation (TSE:4118) announces an Equity Buyback for 2,300,000 shares, representing 3.42% for ¥10,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 2,300,000 shares, representing 3.42% of the outstanding shares for ¥10,000 million. The purpose of the program is to improve shareholder value and to implement a flexible capital policy in response to changes in the business environment. The program will run until March 24, 2022. As of August 31, 2022, the company had 67,195,241 shares outstanding and 804,759 shares in treasury.
Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥161 (vs JP¥119 in 1Q 2022)First quarter 2023 results: EPS: JP¥161 (up from JP¥119 in 1Q 2022). Revenue: JP¥192.7b (up 17% from 1Q 2022). Net income: JP¥10.5b (up 36% from 1Q 2022). Profit margin: 5.5% (up from 4.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.2%, compared to a 2.9% growth forecast for the industry in Germany.
공시 • Jun 11Kaneka Corporation to Report Q1, 2023 Results on Aug 10, 2022Kaneka Corporation announced that they will report Q1, 2023 results on Aug 10, 2022
Reported Earnings • May 15Full year 2022 earnings released: EPS: JP¥406 (vs JP¥243 in FY 2021)Full year 2022 results: EPS: JP¥406 (up from JP¥243 in FY 2021). Revenue: JP¥691.5b (up 20% from FY 2021). Net income: JP¥26.5b (up 67% from FY 2021). Profit margin: 3.8% (up from 2.7% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.3%, compared to a 6.4% growth forecast for the industry in Germany.
공시 • May 14Kaneka Corporation, Annual General Meeting, Jun 29, 2022Kaneka Corporation, Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Managing Executive Officer & Director Katsunobu Doro was the last director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Apr 21Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €31.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 9.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings is also forecast to grow by 6.8% per annum over the same time period.
공시 • Apr 13Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) VariantsKaneka Corporation released KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta) ver.2”, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19. This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test. This is expected to help reduce the burden placed by testing and to assist with selecting the best suitable drugs and treatment approaches for each variant in clinical settings. Kaneka has already released the KANEKA Direct RT-PCR Kit SARS-CoV-2, an in-vitro diagnostic reagent that uses Kaneka's original sample processing technology to produce test results in less than an hour, KANEKA RT-PCR Kit “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which can detect four variants simultaneously, and KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta)” which can detect the Delta and Omicron variants of COVID-19. These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers. These products make it possible to quickly test large numbers of samples.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (4.7%).
Reported Earnings • Feb 09Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥111 (up from JP¥110 in 3Q 2021). Revenue: JP¥178.4b (up 15% from 3Q 2021). Net income: JP¥7.26b (up 1.0% from 3Q 2021). Profit margin: 4.1% (down from 4.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.9%. Over the next year, revenue is forecast to stay flat compared to a 6.0% growth forecast for the industry in Germany.
Reported Earnings • Nov 10Second quarter 2022 earnings released: EPS JP¥107 (vs JP¥31.26 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥166.2b (up 19% from 2Q 2021). Net income: JP¥7.01b (up 244% from 2Q 2021). Profit margin: 4.2% (up from 1.5% in 2Q 2021). The increase in margin was driven by higher revenue.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 07 December 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.7%).
Reported Earnings • Aug 14First quarter 2022 earnings released: EPS JP¥119 (vs JP¥6.70 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥164.1b (up 30% from 1Q 2021). Net income: JP¥7.76b (up JP¥7.32b from 1Q 2021). Profit margin: 4.7% (up from 0.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 16Full year 2021 earnings released: EPS JP¥243 (vs JP¥215 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥577.4b (down 4.0% from FY 2020). Net income: JP¥15.8b (up 13% from FY 2020). Profit margin: 2.7% (up from 2.3% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Mar 24Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.6%).
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥39.40, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Chemicals industry in Germany. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €24.18 per share.
공시 • Mar 11Kaneka Corporation to Report Fiscal Year 2021 Results on May 13, 2021Kaneka Corporation announced that they will report fiscal year 2021 results on May 13, 2021
Is New 90 Day High Low • Feb 16New 90-day high: €32.60The company is up 29% from its price of €25.20 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.16 per share.
Reported Earnings • Feb 11Third quarter 2021 earnings released: EPS JP¥110 (vs JP¥48.85 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥154.8b (up 1.4% from 3Q 2020). Net income: JP¥7.18b (up 125% from 3Q 2020). Profit margin: 4.6% (up from 2.1% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Feb 11Revenue beats expectationsRevenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.3%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.
Is New 90 Day High Low • Jan 26New 90-day high: €30.00The company is up 26% from its price of €23.80 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.58 per share.
Is New 90 Day High Low • Jan 08New 90-day high: €29.20The company is up 16% from its price of €25.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.44 per share.
공시 • Dec 17Kaneka Corporation to Report Q3, 2021 Results on Feb 09, 2021Kaneka Corporation announced that they will report Q3, 2021 results on Feb 09, 2021
Is New 90 Day High Low • Dec 17New 90-day high: €28.40The company is up 19% from its price of €23.80 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.62 per share.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 1.1%, compared to a 3.6% growth forecast for the Chemicals industry in Germany.
Is New 90 Day High Low • Nov 12New 90-day high: €25.80The company is up 22% from its price of €21.20 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.41 per share.
Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS JP¥31.26The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥140.1b (down 7.3% from 2Q 2020). Net income: JP¥2.04b (down 20% from 2Q 2020). Profit margin: 1.5% (down from 1.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 12New 90-day high: €25.60The company is up 21% from its price of €21.20 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.76 per share.
Is New 90 Day High Low • Sep 18New 90-day high: €24.80The company is up 8.0% from its price of €23.00 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.11 per share.
공시 • Sep 13Kaneka Corporation to Report Q2, 2021 Results on Nov 10, 2020Kaneka Corporation announced that they will report Q2, 2021 results on Nov 10, 2020
공시 • Jun 28Kaneka Corporation to Report Q1, 2021 Results on Aug 12, 2020Kaneka Corporation announced that they will report Q1, 2021 results on Aug 12, 2020